G1 Therapeutics: Without Cash, The CRC Failure Becomes A Tougher Hurdle (GTHX)

RyanJLane/E+ through Getty Photos

I lined G1 Therapeutics (NASDAQ:GTHX) in November, after they had been speaking about when to topline their colorectal most cancers trial. This was PRESERVE 1, the part 3 metastatic colorectal most cancers (mCRC) trial of trilaciclib, which was totally enrolled in June and was slated to topline in

Back To Top